Company Product Description Indication Status
Genentech, of South San Francisco, a member of the Roche Group, and Halozyme Therapeutics Inc., of San Diego Fixed-dose combination of Perjeta (pertuzumab) and Herceptin (trastuzumab) with hyaluronidase HER2-targeted antibodies with hyaluronidase administered by subcutaneous injection HER2-positive breast cancer FDA accepted the BLA seeking approval for use in combination with intravenous chemotherapy 
Lysogene SA, of Paris LYS-SAF302 Gene therapy designed to deliver functional copy of the SGSH gene to the brain through 1-time direct-to-CNS administration Mucopolysaccharidosis type IIIA FDA granted fast track status
Noxopharm Ltd., of Sydney Veyonda (idronoxil) S1P inhibitor Soft tissue sarcomas FDA cleared IND to test combination with doxorubicin

Notes

For more information about individual companies and/or products, see Cortellis.

No Comments